AU2008258599B2 — Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
Assigned to NSAB Filial af Neurosearch Sweden AB · Expires 2013-06-13 · 13y expired
What this patent protects
The present invention relates to the use of compounds which increase extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically to the use of 3-disubstituted phenyl-1 - pyrrolidinols for the treatm…
USPTO Abstract
The present invention relates to the use of compounds which increase extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically to the use of 3-disubstituted phenyl-1 - pyrrolidinols for the treatment of central nervous system disorders.
Drugs covered by this patent
- Xcopri (CENOBAMATE) · Sk Life
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.